Friday, September 13, 2013


COLIMEX® (Colistin oral) Colistin is produced from a strain of the species Bacillus polymyxa. It acts specifically on gram-negative bacteria and has a rapid bactericidal effect on both resting cells and growing cells. The risk of resistance developing during treatment is minimal. Escherichia coli, Shigella, Salmonella, Pseudomonas, Aerobacter, Klebsiella, and H. influenzae are amongst the strains most sensitive to colistin. 
Most strains of Proteus, Neisseria, and Serratia are resistant. 
Colimex oral preparations (Colistin sulphate) 
As colistin is not absorbed in the intestinal tract, the syrup is 
reserved for treatment of gastrointestinal infections. 
Indic ions Infections caused by susceptible gram-negative bacteria. 
Gastroenteritis and enterocolitis (also in the new born, including 
premature babies and infants) caused by gram- negative strains. 
Bacillary dysentery. 
Side-effects Almost does not occur in the usual oral doses. 
Dosage The usual dosage over 24 hours is 0.15 million units/kg body 
weight, divided into 3-4 doses. Each 5 ml of syrup corresponds to 
0.25 million units (250.000 units) colistin sulphate.